TUCSON, Ariz., April 11, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), (“HTG”), a provider of instruments and reagents for molecular profiling applications, today announced distribution agreements with Gamidor Diagnostics (“Gamidor”) in Israel and Durviz s.l. Parque Tecnológico de Valencia (“Durviz”) in Spain and Portugal to manage distribution of HTG’s next generation sequencing (NGS)-based products.
“By expanding our distribution reach into these markets, we believe the availability of the HTG EdgeSeq system and assays will accelerate the adoption of molecular profiling using NGS,” stated Jean Claude Gerard, PhD, VP European Commercial Operations for HTG Molecular Diagnostics. Dr. Gerard added, “Both Gamidor and Durviz are as passionate as we are at HTG about enabling precision medicine at the local level.”
Gamidor provides systems, chemicals, reagents and services in Israel, offering state-of-the-art diagnostic solutions to hospitals, health management systems and academic research institutes. Durviz is a distributor of next-generation sequencing reagents and library preparation systems in Spain and Portugal.
“These agreements serve to expand HTG's reach outside the United States and we see our agreements with Gamidor and Durviz as models for additional agreements with distributors in select global markets,” stated TJ Johnson, President and CEO of HTG Molecular Diagnostics.
About HTG:
Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with our business, including its ex‑U.S. expansion, the capabilities of our technology, the subject distributor agreements and their expected benefits to us, and ex‑U.S. market development, including the rate of adoption of NGS-based molecular profiling. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with our ability to successfully develop, manufacture and commercialize molecular profiling products, commercializing our products through distributor relationships, and expansion of our ex‑U.S. commercial operations. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Annual Report on Form 10-K for the year ended December 31, 2015. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.